University Hospital in Finland Orders a Nexstim NBS 6 System
Press release, Helsinki, 10 March 2026 at 9 AM (EET)
Nexstim Plc (“Nexstim” or “Company”) has received an order for an NBS 6 diagnostics system from a university hospital in Finland. The customer is an experienced Nexstim system user. After the system delivery, the customer will be able to use both of their NBS 6 Systems integrated with the data management system.
In October 2025, the Nexstim received MDR (Regulation (EU) 2017/745) certification for the NBS 6 for the pre-procedural mapping of the speech and motor cortices of the brain. The NBS 6 system is also CE-marked for the treatment of major depression and chronic neuropathic pain, as well as for the post-operative rehabilitation of motor deficits of the upper limb.
NBS 6 is a new combination system built on Nexstim’s unique, clinically established E-field navigated TMS (transcranial magnetic stimulation) technology, with a modular system concept that allows system capabilities to expand over time and be highly customized based on a customer’s research or clinical interests.
Mikko Karvinen, CEO of Nexstim, comments: “We are happy to see our customers in our home market get access to our new system generation that is now available for both diagnostics and therapy use. This customer gains great benefit from the flexibility and usability that our combination system brings.”